Revolution Medicines Files 8-K
Ticker: RVMDW · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $46.00, $45.9999, $43.93, $43.9299 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: RVMD
TL;DR
RVMD filed an 8-K on Dec 5th, reporting other events and financials as of Dec 3rd.
AI Summary
Revolution Medicines, Inc. filed an 8-K on December 5, 2024, reporting other events and financial statements/exhibits as of December 3, 2024. The company, incorporated in Delaware, is involved in biological products, specifically excluding diagnostics.
Why It Matters
This filing indicates a routine update or disclosure from Revolution Medicines, Inc. to the SEC, potentially containing important operational or financial information for investors.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting events and exhibits, not indicating any immediate material adverse changes.
Key Numbers
- 001-39219 — Commission File Number (SEC identifier for Revolution Medicines, Inc.)
- 47-2029180 — IRS Employer Identification No. (Tax identification number for Revolution Medicines, Inc.)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 001-39219 (company_id) — Commission File Number
- 47-2029180 (company_id) — IRS Employer Identification No.
- 700 Saginaw Drive Redwood City, California 94063 (address) — Principal Executive Offices
- December 3, 2024 (date) — Date of earliest event reported
- December 5, 2024 (date) — Filing date
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the primary business of Revolution Medicines, Inc. according to the filing?
Revolution Medicines, Inc. is engaged in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code [2836].
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 3, 2024.
What is the principal executive office address for Revolution Medicines, Inc.?
The principal executive office address is 700 Saginaw Drive, Redwood City, California 94063.
What is the fiscal year end for Revolution Medicines, Inc.?
The fiscal year end for Revolution Medicines, Inc. is December 31.
Filing Stats: 999 words · 4 min read · ~3 pages · Grade level 10.5 · Accepted 2024-12-05 16:18:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq
- $46.00 — price to the public in the Offering is $46.00 per Share and $45.9999 per Pre-Funded W
- $45.9999 — in the Offering is $46.00 per Share and $45.9999 per Pre-Funded Warrant, which is the pr
- $43.93 — e Shares from the Company at a price of $43.93 per Share and the Pre-Funded Warrants f
- $43.9299 — Warrants from the Company at a price of $43.9299 per Pre-Funded Warrant. In addition, un
- $823.0 m — received net proceeds of approximately $823.0 million, after deducting the Underwriters
Filing Documents
- d865739d8k.htm (8-K) — 33KB
- d865739dex11.htm (EX-1.1) — 289KB
- d865739dex41.htm (EX-4.1) — 75KB
- d865739dex51.htm (EX-5.1) — 19KB
- g865739g1205141824428.jpg (GRAPHIC) — 1KB
- g865739snap1.jpg (GRAPHIC) — 4KB
- 0001193125-24-271540.txt ( ) — 684KB
- rvmdw-20241203.xsd (EX-101.SCH) — 4KB
- rvmdw-20241203_def.xml (EX-101.DEF) — 13KB
- rvmdw-20241203_lab.xml (EX-101.LAB) — 22KB
- rvmdw-20241203_pre.xml (EX-101.PRE) — 14KB
- d865739d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated as of December 3, 2024, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Latham & Watkins LLP. 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: December 5, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer